Old and new mpox vaccine

Paula Jauregui

DOI: https://doi.org/10.1038/s41590-024-01979-7

IF: 30.5

2024-09-28

Nature Immunology

Abstract:Outbreaks of mpox have been increasing over the past few decades. The modified vaccinia Ankara (MVA)-based vaccine is effective against mpox; however, issues such as incomplete immunity and uncertainty of cross-protection to more virulent strains necessitate the investigation of improved vaccines. In Cell , Mucker et al. compare the protection against mpox conferred by two different vaccines in non-human primates. They tested the mRNA-LNP MPXV vaccine, mRNA-1769, that expresses four mpox virus (MPXV) antigens and compared it with the live-attenuated Orthopoxvirus vaccine MVA in cynomolgus macaques after a lethal challenge with MPXV clade I Z79. Both vaccines provided robust protection against lethal MPXV challenge, but mRNA-1769 provided better protection against symptoms such as weight loss, lesion number and duration, and viral replication. By analyzing the humoral immune response, the researchers found that mRNA-1769 immunization elicited robust, neutralizing and broadly cross-reactive antibody responses. Using systems serology, IgG subclass responses and Fc-receptor-binding profiles, the authors found variability in the antibody functions and profiles across vaccine modalities. To define the antibody mechanisms that account for attenuation of disease, the authors performed a multivariate correlates analysis and demonstrated that the effector functions of antibodies specific for extracellular virions and mature virions are important for the reduction of the formation of lesions. This is an important step towards finding a better vaccine for mpox, although more research is needed to understand whether mRNA vaccines can provide the needed immunity for mpox control in humans. Original reference: Cell https://doi.org/10.1016/j.cell.2024.08.043 (2024)

immunology